Faron 2023 Half-Year Financial Results
Faron Pharmaceuticals Ltd. (“Faron” or “the Company”) Faron Reports Half-Year Financial Results, January 1 – June 30, 2023 Company Announcement, August 29, 2023 Summary Highlights (including post-period events) · The US Food and Drug Administration (FDA) granted bexmarilimab Orphan Drug Designation (ODD) for the treatment of acute myeloid leukemia (AML). · The latest data from the Phase I/II BEXMAB study reinforces bexmarilimab’s potential to improve the therapeutic benefit for patients with aggressive hematological malignancies who do not respond